TNSN97074A1 - Dihydrates de mesylate de 5 - (2 - (4 - (1,2 - benzisothiazole - 3 - yl) - 1 - piperazinyl) ethyl) - 6 - chloro - 1,3 - dihydro - 2h - indole - 2 - one. - Google Patents

Dihydrates de mesylate de 5 - (2 - (4 - (1,2 - benzisothiazole - 3 - yl) - 1 - piperazinyl) ethyl) - 6 - chloro - 1,3 - dihydro - 2h - indole - 2 - one.

Info

Publication number
TNSN97074A1
TNSN97074A1 TNTNSN97074A TNSN97074A TNSN97074A1 TN SN97074 A1 TNSN97074 A1 TN SN97074A1 TN TNSN97074 A TNTNSN97074 A TN TNSN97074A TN SN97074 A TNSN97074 A TN SN97074A TN SN97074 A1 TNSN97074 A1 TN SN97074A1
Authority
TN
Tunisia
Prior art keywords
benzisothiazole
piperazinyl
indole
dihydro
chloro
Prior art date
Application number
TNTNSN97074A
Other languages
English (en)
French (fr)
Inventor
Robert Busch Frank
Anne Rose Carol
James Shine Russell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN97074A1 publication Critical patent/TNSN97074A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
TNTNSN97074A 1996-05-07 1997-05-06 Dihydrates de mesylate de 5 - (2 - (4 - (1,2 - benzisothiazole - 3 - yl) - 1 - piperazinyl) ethyl) - 6 - chloro - 1,3 - dihydro - 2h - indole - 2 - one. TNSN97074A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
TNSN97074A1 true TNSN97074A1 (fr) 2005-03-15

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97074A TNSN97074A1 (fr) 1996-05-07 1997-05-06 Dihydrates de mesylate de 5 - (2 - (4 - (1,2 - benzisothiazole - 3 - yl) - 1 - piperazinyl) ethyl) - 6 - chloro - 1,3 - dihydro - 2h - indole - 2 - one.

Country Status (40)

Country Link
US (1) US6245765B1 (en:Method)
EP (1) EP0918772B1 (en:Method)
JP (1) JP3494659B2 (en:Method)
KR (1) KR100333215B1 (en:Method)
CN (1) CN1091769C (en:Method)
AP (1) AP765A (en:Method)
AR (1) AR007004A1 (en:Method)
AT (1) ATE278689T1 (en:Method)
AU (1) AU731267B2 (en:Method)
BG (1) BG63544B1 (en:Method)
BR (1) BR9709889A (en:Method)
CA (1) CA2252898C (en:Method)
CO (1) CO4940466A1 (en:Method)
CZ (1) CZ289215B6 (en:Method)
DE (1) DE69731094T2 (en:Method)
DK (1) DK0918772T3 (en:Method)
DZ (1) DZ2222A1 (en:Method)
EA (1) EA001190B1 (en:Method)
EG (1) EG24076A (en:Method)
ES (1) ES2229342T3 (en:Method)
GT (1) GT199700052A (en:Method)
HR (1) HRP970236B1 (en:Method)
ID (1) ID16867A (en:Method)
IL (1) IL126591A (en:Method)
IS (1) IS2080B (en:Method)
MA (1) MA24171A1 (en:Method)
MY (1) MY119997A (en:Method)
NO (1) NO312514B1 (en:Method)
NZ (1) NZ332218A (en:Method)
OA (1) OA10909A (en:Method)
PL (1) PL188330B1 (en:Method)
PT (1) PT918772E (en:Method)
SI (1) SI0918772T1 (en:Method)
SK (1) SK282837B6 (en:Method)
TN (1) TNSN97074A1 (en:Method)
TR (1) TR199802240T2 (en:Method)
TW (1) TW491847B (en:Method)
UA (1) UA46840C2 (en:Method)
WO (1) WO1997042191A1 (en:Method)
ZA (1) ZA973876B (en:Method)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
ATE391507T1 (de) * 2000-06-02 2008-04-15 Pfizer Prod Inc S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
KR20080022595A (ko) * 2003-06-03 2008-03-11 테바 파마슈티컬 인더스트리즈 리미티드 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
EP1753460A2 (en) * 2004-05-11 2007-02-21 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
CA2591670A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Process of preparing ziprasidone mesylate
US20070032511A1 (en) * 2005-02-11 2007-02-08 Judith Aronhime Amorphous ziprasidone mesylate
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICULAR COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
EP2146577A1 (en) * 2007-05-18 2010-01-27 Scidose, Llc Ziprasidone formulations
CA2727573A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
KR101936968B1 (ko) * 2010-10-18 2019-01-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 주사용 서방형 제제
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
IL126590A (en) 1996-05-07 2001-11-25 Pfizer Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it

Also Published As

Publication number Publication date
ZA973876B (en) 1998-11-06
HK1017892A1 (en) 1999-12-03
AP9700976A0 (en) 1997-07-31
CN1216991A (zh) 1999-05-19
IL126591A0 (en) 1999-08-17
CA2252898C (en) 2003-04-08
SK150898A3 (en) 2000-02-14
IS2080B (is) 2006-02-15
CZ349398A3 (cs) 1999-09-15
CA2252898A1 (en) 1997-11-13
SK282837B6 (sk) 2002-12-03
OA10909A (en) 2001-10-26
ID16867A (id) 1997-11-20
NO312514B1 (no) 2002-05-21
WO1997042191A1 (en) 1997-11-13
KR100333215B1 (ko) 2002-06-20
DZ2222A1 (fr) 2002-12-03
AU2174797A (en) 1997-11-26
JP3494659B2 (ja) 2004-02-09
EP0918772B1 (en) 2004-10-06
UA46840C2 (uk) 2002-06-17
HRP970236A2 (en) 1998-06-30
PL188330B1 (pl) 2005-01-31
ES2229342T3 (es) 2005-04-16
AR007004A1 (es) 1999-10-13
NO985194D0 (no) 1998-11-06
DK0918772T3 (da) 2005-01-10
GT199700052A (es) 2001-08-29
PT918772E (pt) 2004-12-31
KR20000010824A (ko) 2000-02-25
CO4940466A1 (es) 2000-07-24
NO985194L (no) 1998-11-06
BG102892A (en) 1999-09-30
AU731267B2 (en) 2001-03-29
SI0918772T1 (en) 2005-02-28
BR9709889A (pt) 1999-08-10
IS4874A (is) 1998-10-20
JPH11509867A (ja) 1999-08-31
PL329884A1 (en) 1999-04-12
TR199802240T2 (en:Method) 1999-02-22
CZ289215B6 (cs) 2001-12-12
HRP970236B1 (en) 2002-12-31
EA001190B1 (ru) 2000-12-25
DE69731094D1 (de) 2004-11-11
MA24171A1 (fr) 1997-12-31
CN1091769C (zh) 2002-10-02
MY119997A (en) 2005-08-30
IL126591A (en) 2001-11-25
ATE278689T1 (de) 2004-10-15
BG63544B1 (bg) 2002-04-30
DE69731094T2 (de) 2006-02-23
EP0918772A1 (en) 1999-06-02
TW491847B (en) 2002-06-21
US6245765B1 (en) 2001-06-12
AP765A (en) 1999-09-17
EA199800912A1 (ru) 1999-04-29
NZ332218A (en) 2005-02-25
EG24076A (en) 2008-05-11

Similar Documents

Publication Publication Date Title
TNSN97074A1 (fr) Dihydrates de mesylate de 5 - (2 - (4 - (1,2 - benzisothiazole - 3 - yl) - 1 - piperazinyl) ethyl) - 6 - chloro - 1,3 - dihydro - 2h - indole - 2 - one.
TNSN97073A1 (fr) Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1- piperazinyl)-etyl)-6-chloro-1,3-dihydro-2 h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
IL106777A (en) Monohydrate of 5-(2-(4-(1, 2-benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6- chloro-1, 3-dihydro-2h- indole-2-one hydrochloride and pharmaceutical compositions comprising it
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97192A1 (fr) Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97144A1 (fr) Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
MA25493A1 (fr) Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux.
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2923A1 (fr) Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation.
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
MA26914A1 (fr) Derives bicycliques substitues pour le traitement d'une croissance cellulaire anormale
TNSN04167A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar
DZ2114A1 (fr) Procédé pour la préparation du d-tartrate de (-)-cis-6(s)-phényl-5}4-(2-pyrrolidine-1-ylethoxy)-phénylÜ-5,6,7,8-tétrahydronaphtalène-2-ol.
MA26523A1 (fr) Modification thermodynamiquement stable de 1-(4-carbazolyloxy)-3-(2-(2-methoxyphenoxy) ethylamino)-2-propanole, procede pour sa preparation et compositions pharmaceutiques le comprenant
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
MX9701116A (es) Profarmacos de 5-(2-[4-(1,2-benzoisotiazol-3-il)-1-piperazinil]etil)-6-clor o-1,3-dihidro-2h-indol-2-ona.
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
YU26700A (sh) Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
TNSN00105A1 (fr) Derives de 1-trifluoromethyl-4-hydroxy-7-piperidinyl- aminomethylchromane, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2742038B1 (fr) Manche orthopedique porte-rape ou porte-implant, adapte pour supporter une rape ou un implant d'un os long tel qu'un humerus
TNSN99104A1 (fr) 3 - cetoderives tricycliques de 6 - 0 - methylerythromycine, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00095A1 (fr) Benzolactames et thioamides cycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2689126B1 (fr) 2-(imino substitué)-thiazolidines, procédé pour les préparer et utilisation pour la préparation des compositions pharmaceutiques.